These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29324842)

  • 21. Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod.
    Abdel-Mohsen M; Deeks S; Giron L; Hong KY; Goldman A; Zhang L; Huang SSY; Verrill D; Guo S; Selzer L; de Vries CR; Vendrame E; SenGupta D; Wallin JJ; Cai Y
    Front Immunol; 2024; 15():1405348. PubMed ID: 38979421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.
    Li JZ; Etemad B; Ahmed H; Aga E; Bosch RJ; Mellors JW; Kuritzkes DR; Lederman MM; Para M; Gandhi RT
    AIDS; 2016 Jan; 30(3):343-53. PubMed ID: 26588174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir.
    Calin R; Hamimi C; Lambert-Niclot S; Carcelain G; Bellet J; Assoumou L; Tubiana R; Calvez V; Dudoit Y; Costagliola D; Autran B; Katlama C;
    AIDS; 2016 Mar; 30(5):761-9. PubMed ID: 26730568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harnessing CD8
    Warren JA; Clutton G; Goonetilleke N
    Front Immunol; 2019; 10():291. PubMed ID: 30863403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features.
    Bartsch YC; Loos C; Rossignol E; Fajnzylber JM; Yuan D; Avihingsanon A; Ubolyam S; Jupimai T; Hirschel B; Ananworanich J; Lauffenburger DA; Li JZ; Alter G; Julg B
    mBio; 2021 Mar; 12(2):. PubMed ID: 33688003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption.
    Barqasho B; Nowak P; Tjernlund A; Kinloch S; Goh LE; Lampe F; Fisher M; Andersson J; Sönnerborg A;
    HIV Med; 2009 Feb; 10(2):94-102. PubMed ID: 19200172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
    Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
    J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
    Castagna A; Muccini C; Galli L; Bigoloni A; Poli A; Spagnuolo V; Nozza S; Racca S; Galli A; Cinque P; Carini E; Lazzarin A
    J Antimicrob Chemother; 2019 Jul; 74(7):2039-2046. PubMed ID: 31225610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity.
    McGuinty M; Angel JB; Cooper CL; Cowan J; MacPherson PA; Kumar A; Murthy S; Sy R; Dennehy M; Tremblay N; Byrareddy SN; Cameron DW
    BMJ Open; 2020 Oct; 10(10):e041359. PubMed ID: 33033101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral Therapy.
    Sneller MC; Huiting ED; Clarridge KE; Seamon C; Blazkova J; Justement JS; Shi V; Whitehead EJ; Schneck RF; Proschan M; Moir S; Fauci AS; Chun TW
    J Infect Dis; 2020 Oct; 222(10):1655-1659. PubMed ID: 32443148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.
    Lee WS; Kristensen AB; Rasmussen TA; Tolstrup M; Østergaard L; Søgaard OS; Wines BD; Hogarth PM; Reynaldi A; Davenport MP; Emery S; Amin J; Cooper DA; Kan VL; Fox J; Gruell H; Parsons MS; Kent SJ
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.
    Sneller MC; Justement JS; Gittens KR; Petrone ME; Clarridge KE; Proschan MA; Kwan R; Shi V; Blazkova J; Refsland EW; Morris DE; Cohen KW; McElrath MJ; Xu R; Egan MA; Eldridge JH; Benko E; Kovacs C; Moir S; Chun TW; Fauci AS
    Sci Transl Med; 2017 Dec; 9(419):. PubMed ID: 29212716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy.
    Blazkova J; Gao F; Marichannegowda MH; Justement JS; Shi V; Whitehead EJ; Schneck RF; Huiting ED; Gittens K; Cottrell M; Benko E; Kovacs C; Lack J; Sneller MC; Moir S; Fauci AS; Chun TW
    Nat Med; 2021 Nov; 27(11):1893-1898. PubMed ID: 34711975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation.
    Liu PT; Keele BF; Abbink P; Mercado NB; Liu J; Bondzie EA; Chandrashekar A; Borducchi EN; Hesselgesser J; Mish M; Chin G; Bekerman E; Geleziunas R; Barouch DH
    Nat Commun; 2020 Oct; 11(1):5412. PubMed ID: 33110078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial.
    Palich R; Ghosn J; Chaillon A; Boilet V; Nere ML; Chaix ML; Delobel P; Molina JM; Lucht F; Bouchaud O; Rieux V; Thiebaut R; Levy Y; Delaugerre C; Lelievre JD;
    AIDS; 2019 Feb; 33(2):279-284. PubMed ID: 30325777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.
    López-Huertas MR; Gutiérrez C; Madrid-Elena N; Hernández-Novoa B; Olalla-Sierra J; Plana M; Delgado R; Rubio R; Muñoz-Fernández MÁ; Moreno S
    Sci Rep; 2020 Dec; 10(1):22286. PubMed ID: 33339855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extensive characterization of HIV-1 reservoirs reveals links to plasma viremia before and during analytical treatment interruption.
    Cole B; Lambrechts L; Boyer Z; Noppe Y; De Scheerder MA; Eden JS; Vrancken B; Schlub TE; McLaughlin S; Frenkel LM; Palmer S; Vandekerckhove L
    Cell Rep; 2022 Apr; 39(4):110739. PubMed ID: 35476994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
    Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
    AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.
    Papasavvas E; Ortiz GM; Gross R; Sun J; Moore EC; Heymann JJ; Moonis M; Sandberg JK; Drohan LA; Gallagher B; Shull J; Nixon DF; Kostman JR; Montaner LJ
    J Infect Dis; 2000 Sep; 182(3):766-75. PubMed ID: 10950770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.